Ibrutinib Capsules And Tablets Suppliers & Bulk Manufacturers
Available Forms: Capsules and tablets
Available Strengths: Capsule:140 mg, 70 mg; Tablet: 140 mg
Reference Brands: Imbruvica®(US & EU)
Category:
Oncology Cancer Care
Ibrutinib (brand name Imbruvica®) is a BTK inhibitor used to treat B-cell malignancies like CLL, MCL, and Waldenström's macroglobulinemia. It works by blocking Bruton’s tyrosine kinase to prevent cancerous B-cell growth. Available in oral capsules (70 mg, 140 mg) and oral tablets (140 mg), it is approved in both the US and EU. Marketed by AbbVie and Janssen Pharmaceuticals, Imbruvica® is a crucial B2B oncology product for healthcare providers.
Ibrutinib Capsules and tablets is available in Capsules and tablets
and strengths such as Capsule:140 mg, 70 mg; Tablet: 140 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ibrutinib Capsules and tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ibrutinib Capsules and tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ibrutinib (brand name Imbruvica®) is a BTK inhibitor used in oncology and hematology to treat B-cell malignancies like chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia. By blocking Bruton’s tyrosine kinase (BTK), Ibrutinib disrupts B-cell signaling, preventing cancerous B-cell growth. Available in oral capsules (70 mg, 140 mg) and oral tablets (140 mg), it is approved for use in both the US and EU. Marketed by AbbVie and Janssen Pharmaceuticals, Imbruvica® is a key product for B2B pharmaceutical transactions in the oncology and hematology sectors.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing